[Control of anticoagulant therapy with coumarin derivatives. Evolution of the tests used and their standardization].

Levels of hypocoagulabity induced with coumarin derivatives (aconocoumarin) were determined in 10 patients Quick's test was used to calibrate commercially available thromboplastin reagents against a reference reagent. The results were then standardised in the form of a correct prothrombin ratio. It was found that comparable results could be obtained, even with poorly sensitive thromboplastins, by determining a thromboplastin sensitivity index and using it to convert the prothrombin ratio obtained with each thromboplastin into a "correct" ratio, i.

[Interaction between anti-aggregating and anticoagulant agents. A double blind study on the concomitant administration of nicergoline and acenocoumarols].

A double blind study was carried out comparing 10-methoxy-1,6-dimethyl-ergoline-8 beta-methanol-(5-bromonicotinate) (nicergoline, Sermion) and placebo in 60 thromboembolic patients on long-term controlled acenocoumarol treatment. Aim of the trial was to assess the hypothesis of an interaction on both the coagulatory parameters and the clinical findings. No significant variations of the acenocoumarol daily dose were required in nicergoline treated group and no interaction was demonstrated in coagulatory parameters.

[Natural plasma inhibitors of factors activated by coagulation. Their behavior under various clinical conditions].

Levels of anti-Xa and anti-thrombin III activity have been determined in a series of patients clinically definable as "thrombophiliac" and of women undergoing oestroprogestinic contraceptive treatment. The levels of plasma Co-Ep activity for potentiating anti-Xa activity on the part of differing in vitro added doses of Ep have also been determined. The fact that anti-Xa fell in more marked a fashion than the corresponding anti-thrombin III may be the humoral equivalent of a condition of plasma hypercoagulability.